FXYD6 antibody is a research tool designed to target the FXYD6 protein, a member of the FXYD family of small membrane proteins that regulate ion transport by modulating the activity of Na+/K+-ATPase. FXYD6. also known as phosphohippolin, is primarily expressed in the brain, kidneys, and testes, where it plays a role in maintaining ion homeostasis and cellular excitability. Its interaction with Na+/K+-ATPase suggests involvement in neurological functions, including synaptic plasticity and signal transduction.
FXYD6 antibodies are typically developed as polyclonal or monoclonal reagents for applications such as Western blotting, immunohistochemistry, and immunofluorescence. These antibodies aid in studying FXYD6's expression patterns, localization, and physiological roles. Research has linked FXYD6 dysregulation to neurological disorders, such as epilepsy and cognitive impairments, as well as certain cancers, where altered ion transport may influence tumor progression.
Recent studies also explore FXYD6's potential as a biomarker or therapeutic target. However, its precise mechanisms remain partially unclear, necessitating further investigation. Validation of FXYD6 antibodies includes specificity checks via knockout controls or siRNA silencing to ensure reliable detection. As interest in ion channel-related pathologies grows, FXYD6 antibodies continue to support advances in understanding cellular physiology and disease mechanisms.